<DOC>
	<DOCNO>NCT02611323</DOCNO>
	<brief_summary>This study evaluate safety , efficacy , pharmacokinetics induction treatment obinutuzumab , polatuzumab vedotin , venetoclax participant relapse refractory FL , rituximab , polatuzumab vedotin , venetoclax participant DLBCL . Participants FL achieve complete response ( CR ) , partial response ( PR ) , stable disease ( SD ) end induction therapy receive post-induction treatment obinutuzumab venetoclax , participant DLBCL achieve CR PR end induction ( EOI ) receive post-induction treatment rituximab venetoclax .</brief_summary>
	<brief_title>A Study Obinutuzumab , Rituximab , Polatuzumab Vedotin , Venetoclax Relapsed Refractory Follicular Lymphoma ( FL ) Diffuse Large B-Cell Lymphoma ( DLBCL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 For obinutuzumab + polatuzumab vedotin + venetoclax treatment group , relapse refractory FL treatment least one prior chemoimmunotherapy regimen include anticluster differentiation 20 ( CD20 ) ( antiCD20 ) monoclonal antibody ( mAb ) appropriate treatment option exists , determine investigator For rituximab + polatuzumab vedotin + venetoclax treatment group , relapse refractory DLBCL treatment least one prior chemoimmunotherapy regimen include antiCD20 mAb curative option exists determine investigator At least one bidimensionally measurable lesion Known CD20negative status relapse progression Prior allogeneic stem cell transplantation ( SCT ) , autologous SCT within 100 day prior Day 1 Cycle 1 Grade 3b FL History transformation indolent disease DLBCL Current use systemic corticosteroid great ( &gt; ) 20 milligram ( mg ) prednisone per day ( equivalent ) ; prior anticancer therapy include : radioimmunoconjugate within 12 week ; mAb antibodydrug conjugate within 4 week ; radiotherapy/chemotherapy/hormone therapy/targeted smallmolecule therapy within 2 week prior Day 1 Cycle 1 Central nervous system ( CNS ) disease Active infection Actual potential cytochrome P450 ( CYP ) 3A interaction include : requirement warfarin ; use strong moderate CYP3A inhibitor inducer within 7 day prior first dose venetoclax ; consumption grapefruit , Seville oranges , star fruit within 3 day prior first dose venetoclax Positive human immunodeficiency virus ( HIV ) hepatitis B C Receipt live virus vaccine within 28 day prior Day 1 Cycle 1 Poor hematologic , renal , hepatic function Pregnant lactating woman Life expectancy &lt; 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>